Logo image of KRRO

KORRO BIO INC (KRRO) Stock Fundamental Analysis

NASDAQ:KRRO - Nasdaq - US5009461089 - Common Stock - Currency: USD

14.8  -2.87 (-16.24%)

After market: 13.78 -1.02 (-6.89%)

Fundamental Rating

2

KRRO gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 563 industry peers in the Biotechnology industry. KRRO has a great financial health rating, but its profitability evaluates not so good. KRRO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year KRRO has reported negative net income.
KRRO had a negative operating cash flow in the past year.
KRRO had negative earnings in each of the past 5 years.
In the past 5 years KRRO always reported negative operating cash flow.
KRRO Yearly Net Income VS EBIT VS OCF VS FCFKRRO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M -80M

1.2 Ratios

With a Return On Assets value of -36.94%, KRRO perfoms like the industry average, outperforming 58.97% of the companies in the same industry.
Looking at the Return On Equity, with a value of -52.10%, KRRO is in the better half of the industry, outperforming 63.06% of the companies in the same industry.
Industry RankSector Rank
ROA -36.94%
ROE -52.1%
ROIC N/A
ROA(3y)-50.75%
ROA(5y)-35.9%
ROE(3y)-63.13%
ROE(5y)-44.24%
ROIC(3y)N/A
ROIC(5y)N/A
KRRO Yearly ROA, ROE, ROICKRRO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80 -100

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KRRO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KRRO Yearly Profit, Operating, Gross MarginsKRRO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K -4K

More info and screens

7

2. Health

2.1 Basic Checks

KRRO does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, KRRO has more shares outstanding
Compared to 5 years ago, KRRO has less shares outstanding
There is no outstanding debt for KRRO. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
KRRO Yearly Shares OutstandingKRRO Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
KRRO Yearly Total Debt VS Total AssetsKRRO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

KRRO has an Altman-Z score of -1.10. This is a bad value and indicates that KRRO is not financially healthy and even has some risk of bankruptcy.
KRRO's Altman-Z score of -1.10 is fine compared to the rest of the industry. KRRO outperforms 60.21% of its industry peers.
KRRO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.1
ROIC/WACCN/A
WACC10.13%
KRRO Yearly LT Debt VS Equity VS FCFKRRO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

KRRO has a Current Ratio of 8.79. This indicates that KRRO is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of KRRO (8.79) is better than 76.02% of its industry peers.
KRRO has a Quick Ratio of 8.79. This indicates that KRRO is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 8.79, KRRO is doing good in the industry, outperforming 76.02% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 8.79
Quick Ratio 8.79
KRRO Yearly Current Assets VS Current LiabilitesKRRO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 88.77% over the past year.
Measured over the past years, KRRO shows a very negative growth in Revenue. The Revenue has been decreasing by -39.89% on average per year.
EPS 1Y (TTM)88.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.19%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-45.55%
Revenue growth 5Y-39.89%
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, KRRO will show a decrease in Earnings Per Share. The EPS will decrease by -7.44% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-14.04%
EPS Next 2Y-5.05%
EPS Next 3Y-6.52%
EPS Next 5Y-7.44%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KRRO Yearly Revenue VS EstimatesKRRO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
KRRO Yearly EPS VS EstimatesKRRO Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KRRO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KRRO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KRRO Price Earnings VS Forward Price EarningsKRRO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KRRO Per share dataKRRO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10 15

4.3 Compensation for Growth

KRRO's earnings are expected to decrease with -6.52% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.05%
EPS Next 3Y-6.52%

More info and screens

0

5. Dividend

5.1 Amount

KRRO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

KORRO BIO INC

NASDAQ:KRRO (5/6/2025, 8:20:48 PM)

After market: 13.78 -1.02 (-6.89%)

14.8

-2.87 (-16.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2025-03-18/bmo
Earnings (Next)05-20 2025-05-20/amc
Inst Owners102.61%
Inst Owner Change0%
Ins Owners0.43%
Ins Owner Change0%
Market Cap138.97M
Analysts85.33
Price Target124.06 (738.24%)
Short Float %11.37%
Short Ratio10.09
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)12.88%
Min EPS beat(2)10.66%
Max EPS beat(2)15.11%
EPS beat(4)4
Avg EPS beat(4)7.75%
Min EPS beat(4)0.53%
Max EPS beat(4)15.11%
EPS beat(8)6
Avg EPS beat(8)-116.23%
EPS beat(12)9
Avg EPS beat(12)-74.42%
EPS beat(16)9
Avg EPS beat(16)-95.59%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.13%
PT rev (3m)-11.13%
EPS NQ rev (1m)0.37%
EPS NQ rev (3m)-2.69%
EPS NY rev (1m)2.01%
EPS NY rev (3m)-5.91%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)157.15%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 61.19
P/FCF N/A
P/OCF N/A
P/B 0.87
P/tB 0.87
EV/EBITDA N/A
EPS(TTM)-9.39
EYN/A
EPS(NY)-10.71
Fwd EYN/A
FCF(TTM)-8.3
FCFYN/A
OCF(TTM)-6.4
OCFYN/A
SpS0.24
BVpS17.08
TBVpS17.08
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -36.94%
ROE -52.1%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.75%
ROA(5y)-35.9%
ROE(3y)-63.13%
ROE(5y)-44.24%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 502.16%
Cap/Sales 788.29%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 8.79
Quick Ratio 8.79
Altman-Z -1.1
F-Score4
WACC10.13%
ROIC/WACCN/A
Cap/Depr(3y)307.52%
Cap/Depr(5y)347.56%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)88.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%91.19%
EPS Next Y-14.04%
EPS Next 2Y-5.05%
EPS Next 3Y-6.52%
EPS Next 5Y-7.44%
Revenue 1Y (TTM)N/A
Revenue growth 3Y-45.55%
Revenue growth 5Y-39.89%
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-3.8%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y10.71%
OCF growth 3YN/A
OCF growth 5YN/A